
TB006 Expanded Access (EA) Compassionate Use
Alzheimer DiseaseThis is an open-label, expanded access, compassionate use treatment protocol of TB006 treatment in participants who meet clinical diagnostic criteria for Alzheimer's disease (AD). Participants will receive TB006 at a dose of 4,000 milligrams (mg) intravenous (IV) over 1 hour every 28 days ± 5 days.

Expanded Access Program for SNDX-5613
Relapsed/Refractory Acute LeukemiaThis expanded access program will provide an investigational treatment option in a controlled clinical setting for patients who are not otherwise eligible to participate in a clinical study and have no approved treatment options.

A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
Waldenström MacroglobulinemiaThis is a multicenter expanded access study of zanubrutinib monotherapy for participants with B-cell malignancies who are ineligible to enroll into any available zanubrutinib clinical trials

Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
Primary HyperoxaluriaThe purpose of this study is to provide expanded access to lumasiran for adults and pediatric patients with Primary Hyperoxaluria Type 1 (PH1),

A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in...
Small Cell Lung CancerThis is an expanded access program in the USA to enable eligible patients with previously treated small cell lung cancer to access lurbinectedin treatment prior to FDA approval. Sites must apply to participate in the program. A medical doctor must assess whether the potential benefit outweighs the risk of the investigational therapy considering the program eligibility criteria and the individual patient's medical history.

Expanded Access - Autologous Human Schwann Cells in Peripheral Nerve Repair
Peripheral Nerve InjuriesEmergency expanded access for a single patient was granted to receive autologous human Schwann cell (ahSC) augmentation of nerve autograft repair after severe peripheral nerve injury (PNI).

Managed Access Program (MAP)* to Provide Access to Asciminib for Patients With CML in Chronic Phase...
Chronic Myeloid LeukemiaThis program provides access to asciminib for patients with CML in chronic phase (CP) without documented T315I mutation after failure to or intolerance of two prior TKI OR patients in CML-CP with documented T315I mutation and without comparable or satisfactory alternative therapy to treat the disease

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation...
Non Small Cell Lung CancerMedullary Thyroid Cancer5 moreExpanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who...
Critical Limb Ischemia (CLI)A Phase III study of PLX-PAD for CLI patients with minor tissue loss who are unsuitable for revascularization has been initiated (PLX-CLI-03, PACE study). In parallel, this expanded access program (EAP) will be conducted to allow the treatment of patients who are ineligible to be enrolled in the PACE study. The EAP treatment is administered in addition to standard of care of the subjects.PLX-PAD 300×106 cells in a mixture containing 10% DMSO, 5% human serum albumin and Plasma-Lyte, will be administered via 30 IM injections (0.5 mL each) delivered into the leg twice,at 8 weeks interval. The locations of injections of the PLX-PAD are detailed in Appendix 1. Antihistamine treatment should be given at least 1 hour and no more than 1.5 hours prior to PLXPAD administration to ensure coverage for 24 hours, and as long as necessary post PLX-PAD treatment. Consider treatment with second generation H1 inhibitors such as Cetirizine 10 mg once per day.Subjects will be followed-up until 12 months after the 2nd treatment according to the schedule of routine medical visits at the medical institutions. In addition to this routine follow-up, a phone call will be made 12 months after 2nd treatment to inquire on the occurrence of subsequent intervention, amputation, or death.

Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma...
Expanded access use of INCB054329 to treat a single patient with metastatic renal cell carcinoma.